Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Editorial

New CMAJ policy on sharing data from clinical research

John Fletcher
CMAJ February 18, 2014 186 (3) 163; DOI: https://doi.org/10.1503/cmaj.140041
John Fletcher
John Fletcher is Editor-in-Chief, .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Beginning Apr. 1, 2014, CMAJ will require authors of clinical trials of drugs and medical devices to include a data-sharing statement in their manuscripts; however, we will not require authors to agree to share their data, regardless of the study design. We will welcome data-sharing statements for all research articles, but statements will be mandatory only for clinical trials. In their statements, authors should indicate whether any, all or portions of the data are available to others; where, through whom, when and on what terms data will be available; and how data may be accessed.

Some medical journals, such as BMJ and PLoS Medicine, have encouraged data sharing for several years, and last year BMJ made data sharing a condition of publication for trials. CMAJ is adopting a voluntary policy. Why? We know that many researchers are pleased to collaborate in a transparent way and are willing to allow others access to their data. For them, no compulsion is needed. However, two groups have a strong interest to resist initiatives to share data widely. First, those who sell a product or service and have conducted research stand to lose sales if they disclose information that is unfavourable. Drug companies have argued strongly that data from clinical trials are commercial in confidence, and many companies have resisted calls to make their data more widely available. Second, some researchers, who must “publish or perish,” and rely on their data as a resource for several of their articles stand to lose publishing opportunities if they disclose all of their data before they have found the time or resources to complete all of their planned publications.

Because the two groups with the most to lose are the same groups who currently have control of the data, meaningful change will not take place without first addressing their needs. Researchers can protect their interests by paying close attention to data definitions and timing. For example, researchers could release restricted datasets that are relevant only to reported analyses at the time of publication and release the full dataset within a few years. For the manufacturers of drugs and devices the problem is thornier. Companies pay for research as part of the licensing process and may claim ownership of the information produced. However, society demands access to this research through product licensing regulations, and participants in research usually take part in trials believing they are contributing to a common good and not just to a company’s bottom line. Regulators or other large organizations must address these competing interests.

The Nordic Cochrane Centre and BMJ have fuelled the present interest in data sharing by asking for full disclosure of clinical trial data surrounding the effectiveness of Tamiflu (oseltamivir), a drug that has been stockpiled in large quantities in developed countries as part of emergency planning for a possible influenza pandemic.1 Despite their best efforts to obtain data, researchers say that about 60% of the trial data concerning Tamiflu remains hidden.2

Encouraging open sharing of data on a voluntary basis has its own benefits, even if it cannot directly combat intentional concealment. Data sharing could provide answers to the following questions: Did they get it right? Did they miss anything important? Can we use these data to learn more?

Ensuring the credibility of published research is the central focus of academic peer review, yet this process is a notoriously poor detector of error or fraud. Existing editorial policies allow editors to ask authors for their original data as part of the peer review process. However, an individual paper is often reviewed by only a handful of people before publication. Extending the scrutiny of the underlying data into the post-publication period is a logical step.

Sharing data may also benefit society by allowing new knowledge to be generated in ways that would not be possible without cooperation. For example, the effects of interventions are seldom uniform and may vary across different populations of patients. The analyses to detect such subgroup effects and to enable physicians to personalize treatment options require large amounts of data. Without access to individual patient data, such analyses are impossible.

Fortunately, there are early adopters who are already embracing the practice of data sharing. Data from the Canadian Community Health Survey are available to any Canadian researcher with a reasonable research question and an analytic plan. GlaxoSmithKline has an online registry of all its trials and says it will allow scientists to request access to anonymized patient-level data.2 Researchers who wish to share their data may use websites such as www.datadryad.org to do so. By joining these early adopters, CMAJ hopes to encourage Canadian researchers to embrace a new norm, so society can check that they did the right thing, see that nothing has been missed and ask to use the data to generate new knowledge.

Footnotes

  • Competing interests: See www.cmaj.ca/site/misc/cmaj_staff.xhtml

References

  1. ↵
    Tamiflu campaign. BMJ 2014. Available: www.bmj.com/tamiflu (accessed 2014 Jan. 13)
  2. ↵
    1. Collier R
    . UK Parliament calls for sharing of all clinical trial data. CMAJ 2014; Jan. 13 [Epub ahead of print].
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 186 (3)
CMAJ
Vol. 186, Issue 3
18 Feb 2014
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
New CMAJ policy on sharing data from clinical research
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New CMAJ policy on sharing data from clinical research
John Fletcher
CMAJ Feb 2014, 186 (3) 163; DOI: 10.1503/cmaj.140041

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
New CMAJ policy on sharing data from clinical research
John Fletcher
CMAJ Feb 2014, 186 (3) 163; DOI: 10.1503/cmaj.140041
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Coming soon: CMAJ policy on data sharing
  • New CMAJ policy on sharing study data
  • Google Scholar

More in this TOC Section

  • Trouver, tester, « tracer » et isoler énergiquement pour battre la COVID-19
  • Intégration des essais randomisés dans les soins cliniques : comment le Canada peut faire mieux
  • Soins continus et COVID-19 : Qu’une telle tragédie ne se reproduise plus au Canada!
Show more Editorial

Similar Articles

Collections

  • Topics
    • Public health
    • Journalology & publication ethics
    • CMAJ editorial policy

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire